Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Biotech Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Biotech Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: biotech, biotechnology, biopharma, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Biotech.

Generated with SpeculatingStocks Stock Theme Analytics Algorithm™ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to biotech; however, a few may just somewhat depend and/or be indirectly related to biotech. As always complete your own due diligence.


Biotech Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































3.394B


































114.735B




























































































































































































































































































































































































191.956B












148.498B




























































57.998B























































Recent Biotech Headlines




04/19/2018: China's pharmaceutical industry is poised for major growth



04/18/2018: ( IPCI IPCI.T ) Intellipharmaceutics Announces First Quarter 2018 Results



04/17/2018: Alder BioPharmaceuticals(R) Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer



04/11/2018: Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'



04/11/2018: Harry Boxer’s five biotech stocks to watch



04/09/2018: Biotech activist Alex Denner's next target: Ironwood Pharma



03/29/2018: Netflix, biotech Nektar among the biggest market winners in the first quarter



03/28/2018: Aetna will pass drug discounts along to some members at the pharmacy counter



03/27/2018: Pharma bro Martin Shkreli appeals fraud conviction as judge mulls restitution award



03/27/2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA(R) 24 mg for acute gastroenteritis at the SAEM 2018 Annual...



03/27/2018: Aetna to pass on drug rebates to some its members



03/24/2018: Charting the Market



03/22/2018: US could target 10 Chinese industries including new energy vehicles, biopharma



03/21/2018: Healthcare Companies Capitalizing on a Resurgent Biotech Industry



03/17/2018: ( IPCI IPCI.T ) Intellipharmaceutics Announces Closing of US$3.5 Million Financing



03/15/2018: Navidea Biopharmaceuticals to Present at 25(th) Annual Future Leaders in the Biotech Industry



03/15/2018: Ex-Apple chief: Centene partnership with pharmacy start-up will drive better care with lower costs



03/14/2018: Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer



03/14/2018: RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds



03/09/2018: 'Pharma bro' Martin Shkreli sentenced to 7 years in prison



03/09/2018: Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results



03/09/2018: 'Pharma Bro' Shkreli to be sentenced for defrauding investors



03/06/2018: Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28t...



03/05/2018: Strongbridge Biopharma plc to Present KEVEYIS(R) (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American...



03/05/2018: Benitec Biopharma Launches its Phase 2 Oncology Study in Australia



03/01/2018: Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financ...




Recent Biotech Posts (Pulses)




04/20/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.75. -- Go to this Pulse Post



04/19/2018: $BNTCW (Benitec Biopharma Limited) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



04/19/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.77. -- Go to this Pulse Post



04/19/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



04/19/2018: $RDHL (RedHill Biopharma Ltd.) is significantly more volatile than the overall market with a Beta of 1.21. -- Go to this Pulse Post



04/19/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.8. -- Go to this Pulse Post



04/19/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.79. -- Go to this Pulse Post



04/18/2018: $INNT (Innovate Biopharmaceuticals Inc.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



04/18/2018: $ACRX AcelRx announced the publication of an analysis of the pharmacokinetic characteristics of sublingually administered tablets containing 15 or 30 mcg of sufentanil in peer-reviewed journal, Anesthesiology. -- Go to this Pulse Post



04/17/2018: $KERX (Keryx Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



04/17/2018: $HEB (Hemispherx Biopharma, Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $909,000. -- Go to this Pulse Post



04/17/2018: $HEB (Hemispherx Biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(1.99M). -- Go to this Pulse Post



04/17/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.73. -- Go to this Pulse Post



04/17/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



04/17/2018: $ABUS (Arbutus Biopharma Corporation) is significantly more volatile than the overall market with a Beta of 2.22. -- Go to this Pulse Post



04/17/2018: $CUE (Cue Biopharma Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $60.13M. -- Go to this Pulse Post



04/17/2018: $CUE (Cue Biopharma Inc.) did not produce a profit last quarter with Quarterly Net Income of $(10.44M). -- Go to this Pulse Post



04/17/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.74. -- Go to this Pulse Post



04/16/2018: $TBPH (Theravance Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 1.49. -- Go to this Pulse Post



04/16/2018: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 84.57%. -- Go to this Pulse Post



04/16/2018: $SBFM (Sunshine Biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(80,554). -- Go to this Pulse Post



04/16/2018: $SBFM (Sunshine Biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(211,479). -- Go to this Pulse Post



04/16/2018: $ALBO Albireo Pharma reported data on pharmacodynamic marker for A4250; Correlation observed between reduction in serum bile acids and autotaxin with A4250. -- Go to this Pulse Post



04/15/2018: $KERX (Keryx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.76. -- Go to this Pulse Post



04/15/2018: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 71.90%. -- Go to this Pulse Post



04/15/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.66. -- Go to this Pulse Post



04/15/2018: $XTLB (XTL Biopharmaceuticals Ltd.) did not produce a profit last quarter with Quarterly Net Income of $(7,020). -- Go to this Pulse Post



04/15/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(9,524). -- Go to this Pulse Post



04/15/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $1.42M. -- Go to this Pulse Post



04/15/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.16. -- Go to this Pulse Post



04/15/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.77. -- Go to this Pulse Post



04/15/2018: $ABIO (ARCA biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.67. -- Go to this Pulse Post



04/14/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.62. -- Go to this Pulse Post



04/12/2018: $ABUS Arbutus Biopharma and Roivant Sciences entered into an agreement to launch Genevant Sciences; Roivant will contribute $37.5M in transaction-related seed capital. -- Go to this Pulse Post



04/12/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



04/11/2018: $ABUS Arbutus Biopharma and Roivant Sciences entered into an agreement to launch Genevant Sciences; Roivant will contribute $37.5M in transaction-related seed capital. -- Go to this Pulse Post



04/11/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.69. -- Go to this Pulse Post



04/09/2018: $SPY Stocks break out to session highs (SPY +1.2%), lead by biotech and technology sectors. -- Go to this Pulse Post



04/07/2018: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.08. -- Go to this Pulse Post



04/07/2018: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.88. -- Go to this Pulse Post



04/07/2018: $CUE (Cue Biopharma Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



04/06/2018: $INCY IDO inhibitor stocks Incyte (INCY) and NewLink (NLNK) leading oncology, biotech stocks lower after Incyte's failed Phase 3 melanoma data combined with Merck's Keytruda. -- Go to this Pulse Post



04/05/2018: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 96.90%. -- Go to this Pulse Post



04/05/2018: $SPY Stocks extend yesterday's gains after a key reversal off the 200-day moving average: Steel, energy, homebuilders, software and materials leading the market higher while biotech and REITs lag vs. SPY +0.7. -- Go to this Pulse Post



04/05/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.67. -- Go to this Pulse Post



04/05/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 46.34%. -- Go to this Pulse Post



04/04/2018: $SBFM (Sunshine Biopharma, Inc.) is down more than 20%, reaching a new downside threshold. -- Go to this Pulse Post



04/04/2018: $KERX Keryx Biopharma announced publication of Auryxia phase 3 trial data for iron deficiency anemia in adult patients with chronic kidney disease, not on dialysis, in the online issue of the American Journal of Hematology. -- Go to this Pulse Post



04/03/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



04/02/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 1. -- Go to this Pulse Post



04/02/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is profitable as of at least the last quarter with Quarterly Net Income of $1.35B. -- Go to this Pulse Post



03/31/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/31/2018: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.69. -- Go to this Pulse Post



03/30/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/29/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.68. -- Go to this Pulse Post



03/29/2018: $ABUS (Arbutus Biopharma Corporation) did not produce a profit last quarter with Quarterly Net Income of $(35.93M). -- Go to this Pulse Post



03/29/2018: $RDHL (RedHill Biopharma Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/28/2018: $PVCT (Provectus Biopharmaceuticals, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(102,777). -- Go to this Pulse Post



03/28/2018: $PVCT (Provectus Biopharmaceuticals, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(2.72M). -- Go to this Pulse Post



03/28/2018: $SNNA (Sienna Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(14.13M). -- Go to this Pulse Post



03/28/2018: $SNNA (Sienna Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(11.19M). -- Go to this Pulse Post



03/28/2018: $SNNA (Sienna Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 57.80%. -- Go to this Pulse Post



03/28/2018: $ABIO (ARCA biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/28/2018: $SBBP (Strongbridge Biopharma plc) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $13.14M. -- Go to this Pulse Post



03/28/2018: $SBBP (Strongbridge Biopharma plc) did not produce a profit last quarter with Quarterly Net Income of $(18.75M). -- Go to this Pulse Post



03/27/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.7. -- Go to this Pulse Post



03/27/2018: $ABIO (ARCA biopharma, Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $560,000. -- Go to this Pulse Post



03/27/2018: $ABIO (ARCA biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(4.2M). -- Go to this Pulse Post



03/27/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 66.33%. -- Go to this Pulse Post



03/27/2018: $CUE (Cue Biopharma Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/27/2018: $SBBP (Strongbridge Biopharma plc) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/27/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/27/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/26/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/25/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/24/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/23/2018: $VTVT vTv Therapeutics +10% on news of the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in type 1 diabetes. -- Go to this Pulse Post



03/23/2018: $BNIKF (Benitec Biopharma Limited) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/23/2018: $INBP (Integrated Biopharma Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/23/2018: $BNIKF (Benitec Biopharma Limited) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/23/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/22/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/22/2018: $BNIKF (Benitec Biopharma Limited) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/22/2018: $SNNA Sienna Biopharmaceuticals appointed John Smither as CFO succeeding Richard Peterson who resigned for personal reasons effective March 29. -- Go to this Pulse Post



03/22/2018: $VTVT vTv Therapeutics +10% on news of the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in type 1 diabetes. -- Go to this Pulse Post



03/22/2018: $INNT (Innovate Biopharmaceuticals Inc.) has significant insider ownership of at least 20% with insider ownership of 51.13%. -- Go to this Pulse Post



03/22/2018: $INNT (Innovate Biopharmaceuticals Inc.) is a low float stock with only 0.77M shares in its float. -- Go to this Pulse Post



03/21/2018: $GALE (Galena Biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(12.96M). -- Go to this Pulse Post



03/21/2018: $GALE (Galena Biopharma, Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $61M. -- Go to this Pulse Post



03/21/2018: $BNIKF (Benitec Biopharma Limited) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/21/2018: $SNNA Sienna Biopharmaceuticals appointed John Smither as CFO succeeding Richard Peterson who resigned for personal reasons effective March 29. -- Go to this Pulse Post



03/21/2018: $SBBP Strongbridge Biopharma ticking higher after USPTO issued second method of use patent for RECORLEV. -- Go to this Pulse Post



03/21/2018: $INBP (Integrated Biopharma Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/21/2018: $INNT (Innovate Biopharmaceuticals Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/20/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/20/2018: $SBBP Strongbridge Biopharma ticking higher after USPTO issued second method of use patent for RECORLEV. -- Go to this Pulse Post



03/20/2018: $KMPH KemPharm announced that topline results from its ongoing pediatric and adolescent pharmacokinetic study suggest that following oral administration of its KP415 product candidate, exposure to d-methylphenidate is predictable in patients with ADHD b/t the ages of 6 and 17 years. -- Go to this Pulse Post



03/19/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/19/2018: $SPHRY (Starpharma Holdings Limited) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/19/2018: $SBBP Strongbridge Biopharma presented new data demonstrating that Levoketoconazole is a potent inhibitor of human enzymes controlling cortisol synthesis. -- Go to this Pulse Post



03/18/2018: $ABUS (Arbutus Biopharma Corporation) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $40.08M. -- Go to this Pulse Post



03/18/2018: $ABUS (Arbutus Biopharma Corporation) did not produce a profit last quarter with Quarterly Net Income of $(36.84M). -- Go to this Pulse Post



03/18/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(1.82M). -- Go to this Pulse Post



03/18/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/17/2018: $SNNA (Sienna Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/17/2018: $SNNA (Sienna Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 52.42%. -- Go to this Pulse Post



03/17/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/17/2018: $BNTC (Benitec Biopharma LTD) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/17/2018: $BNTC (Benitec Biopharma LTD) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(7.1M). -- Go to this Pulse Post



03/17/2018: $BNTC (Benitec Biopharma LTD) did not produce a profit last quarter with Quarterly Net Income of $(5.81M). -- Go to this Pulse Post



03/17/2018: $BNTC (Benitec Biopharma LTD) is significantly more volatile than the overall market with a Beta of 4.12. -- Go to this Pulse Post



03/17/2018: $TBPH (Theravance Biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(2.32M). -- Go to this Pulse Post



03/17/2018: $TBPH (Theravance Biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(86.92M). -- Go to this Pulse Post



03/17/2018: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 75.22%. -- Go to this Pulse Post



03/17/2018: $SPHRY (Starpharma Holdings Limited) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(11.29M). -- Go to this Pulse Post



03/17/2018: $SPHRY (Starpharma Holdings Limited) did not produce a profit last quarter with Quarterly Net Income of $(6.23M). -- Go to this Pulse Post



03/17/2018: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.07. -- Go to this Pulse Post



03/17/2018: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.79. -- Go to this Pulse Post



03/17/2018: $BNIKF (Benitec Biopharma Limited) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(7.1M). -- Go to this Pulse Post



03/17/2018: $BNIKF (Benitec Biopharma Limited) did not produce a profit last quarter with Quarterly Net Income of $(5.81M). -- Go to this Pulse Post



03/17/2018: $BNIKF (Benitec Biopharma Limited) is significantly more volatile than the overall market with a Beta of 3.13. -- Go to this Pulse Post



03/17/2018: $ABUS (Arbutus Biopharma Corporation) has significant institutional ownership of at least 20% with institutional ownership of 98.21%. -- Go to this Pulse Post



03/17/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/17/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.73. -- Go to this Pulse Post



03/17/2018: $SBBP (Strongbridge Biopharma plc) is significantly more volatile than the overall market with a Beta of 8.86. -- Go to this Pulse Post



03/17/2018: $SBBP (Strongbridge Biopharma plc) has significant institutional ownership of at least 20% with institutional ownership of 27.04%. -- Go to this Pulse Post



03/16/2018: $NAVB (Navidea Biopharmaceuticals, Inc) did not produce a profit last quarter with Quarterly Net Income of $(6.17M). -- Go to this Pulse Post



03/16/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.84. -- Go to this Pulse Post



03/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(20.47M). -- Go to this Pulse Post



03/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(30.43M). -- Go to this Pulse Post



03/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.65. -- Go to this Pulse Post



03/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 65.30%. -- Go to this Pulse Post



03/16/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.53. -- Go to this Pulse Post



03/16/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.22%. -- Go to this Pulse Post



03/16/2018: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.77. -- Go to this Pulse Post



03/16/2018: $RDHL (RedHill Biopharma Ltd.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(5.93M). -- Go to this Pulse Post



03/16/2018: $RDHL (RedHill Biopharma Ltd.) did not produce a profit last quarter with Quarterly Net Income of $(36.55M). -- Go to this Pulse Post



03/15/2018: $ALDR (Alder Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(10.44M). -- Go to this Pulse Post



03/15/2018: $ALDR (Alder Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(54.36M). -- Go to this Pulse Post



03/15/2018: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 84.09%. -- Go to this Pulse Post



03/15/2018: $EPRSQ (EPIRUS Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(10.65M). -- Go to this Pulse Post



03/15/2018: $EPRSQ (EPIRUS Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(16.27M). -- Go to this Pulse Post



03/15/2018: $INBP (Integrated Biopharma Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/15/2018: $BNTCW (Benitec Biopharma Limited) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(7.1M). -- Go to this Pulse Post



03/15/2018: $BNTCW (Benitec Biopharma Limited) did not produce a profit last quarter with Quarterly Net Income of $(5.81M). -- Go to this Pulse Post



03/15/2018: $BNTCW (Benitec Biopharma Limited) is significantly more volatile than the overall market with a Beta of 3.13. -- Go to this Pulse Post



03/14/2018: $ABIO (ARCA biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/14/2018: $HEB (Hemispherx Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/14/2018: $ABUS (Arbutus Biopharma Corporation) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/14/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/14/2018: $SBFM (Sunshine Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/14/2018: $EPRSQ (EPIRUS Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/14/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 1.93. -- Go to this Pulse Post



03/13/2018: $HEB (Hemispherx Biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/13/2018: $INNT Innovate Biopharmaceuticals named Dr. June Almenoff Chief Operating Officer and Chief Medical Officer. -- Go to this Pulse Post



03/13/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.52. -- Go to this Pulse Post



03/13/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 26.90%. -- Go to this Pulse Post



03/12/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/12/2018: $SBBP Strongbridge Biopharma reported Q4 results. -- Go to this Pulse Post



03/10/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.83. -- Go to this Pulse Post



03/10/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.69. -- Go to this Pulse Post



03/09/2018: $SBFM (Sunshine Biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



03/08/2018: $ALDR (Alder Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.49. -- Go to this Pulse Post



03/08/2018: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 67.57%. -- Go to this Pulse Post



03/08/2018: $INBP (Integrated Biopharma Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/07/2018: $INBP (Integrated Biopharma Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/07/2018: $NEXS (Nexus Biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/05/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.56. -- Go to this Pulse Post



03/05/2018: $ABIO (ARCA biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.19. -- Go to this Pulse Post



03/05/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 26.81%. -- Go to this Pulse Post



03/05/2018: $ABUS (Arbutus Biopharma Corporation) is significantly more volatile than the overall market with a Beta of 2.21. -- Go to this Pulse Post



03/05/2018: $SPY Stocks move to session highs (SPY +0.3%, QQQ +0.2%) with energy, REITs, agriculture and biotech leading the way. -- Go to this Pulse Post



03/05/2018: $SPY Transports, banks, industrials lag while REITs, agriculture and biotech outperform vs. SPY -0.1%. -- Go to this Pulse Post



03/05/2018: $INBP (Integrated Biopharma Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/05/2018: $TBPH (Theravance Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 1.58. -- Go to this Pulse Post



03/05/2018: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 66.95%. -- Go to this Pulse Post



03/04/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.74. -- Go to this Pulse Post



03/04/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.82. -- Go to this Pulse Post



03/04/2018: $NEXS (Nexus Biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/02/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



03/02/2018: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 66.93%. -- Go to this Pulse Post



03/02/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/02/2018: $INBP (Integrated Biopharma Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



03/02/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/01/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/01/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



03/01/2018: $INNT (Innovate Biopharmaceuticals Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



03/01/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.78. -- Go to this Pulse Post



03/01/2018: $RDHL (RedHill Biopharma Ltd.) has significant institutional ownership of at least 20% with institutional ownership of 26.23%. -- Go to this Pulse Post